Antibodies to OspB prevent infection of C3H mice challenged with Borrelia burgdorferi isolates expressing truncated OspB antigens
- PMID: 9041661
- DOI: 10.1016/s0264-410x(96)00123-5
Antibodies to OspB prevent infection of C3H mice challenged with Borrelia burgdorferi isolates expressing truncated OspB antigens
Abstract
Truncation of outer surface protein B (OspB) of the Lyme disease agent, Borrelia burgdorferi, may allow the organism to escape immunological destruction and render an OspB-based vaccine ineffective. To investigate this possibility, we have identified two isolates, 297 and CA4, which predominantly express a truncated form of the OspB antigen. In each case, nucleic acid sequencing revealed that truncation of the OspB antigen resulted from a nonsense mutation within the 3', end of the ospB gene. Growth inhibition and protection studies demonstrated that both isolates were neutralized by an anti-OspB serum. Our results indicate that truncated forms of the OspB antigen possess epitopes that may represent important targets for neutralizing antibodies and thus, support the inclusion of OspB as a component of a subunit vaccine.
Similar articles
-
Evasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B.Proc Natl Acad Sci U S A. 1993 May 1;90(9):4092-6. doi: 10.1073/pnas.90.9.4092. Proc Natl Acad Sci U S A. 1993. PMID: 7683420 Free PMC article.
-
Identification of a highly cross-reactive outer surface protein B epitope among diverse geographic isolates of Borrelia spp. causing Lyme disease.J Clin Microbiol. 1994 Feb;32(2):489-500. doi: 10.1128/jcm.32.2.489-500.1994. J Clin Microbiol. 1994. PMID: 7512097 Free PMC article.
-
Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype.Vaccine. 1993;11(10):1049-54. doi: 10.1016/0264-410x(93)90132-h. Vaccine. 1993. PMID: 8212826
-
Functional heterogeneity in the antibodies produced to Borrelia burgdorferi.Wien Klin Wochenschr. 1999 Dec 10;111(22-23):985-9. Wien Klin Wochenschr. 1999. PMID: 10666815 Review.
-
A recombinant vaccine for Lyme disease.Behring Inst Mitt. 1994 Dec;(95):106-8. Behring Inst Mitt. 1994. PMID: 7755503 Review.
Cited by
-
Outer membrane proteins of pathogenic spirochetes.FEMS Microbiol Rev. 2004 Jun;28(3):291-318. doi: 10.1016/j.femsre.2003.10.004. FEMS Microbiol Rev. 2004. PMID: 15449605 Free PMC article. Review.
-
Protective efficacy of mutant strains of Borrelia burgdorferi as potential reservoir host-targeted biologics against Lyme disease.bioRxiv [Preprint]. 2025 Jul 9:2025.07.09.663885. doi: 10.1101/2025.07.09.663885. bioRxiv. 2025. PMID: 40672219 Free PMC article. Preprint.
-
Therapeutic passive vaccination against chronic Lyme disease in mice.Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12533-8. doi: 10.1073/pnas.94.23.12533. Proc Natl Acad Sci U S A. 1997. PMID: 9356484 Free PMC article.
-
Genome stability of Lyme disease spirochetes: comparative genomics of Borrelia burgdorferi plasmids.PLoS One. 2012;7(3):e33280. doi: 10.1371/journal.pone.0033280. Epub 2012 Mar 14. PLoS One. 2012. PMID: 22432010 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases